An efficient synthesis of two new N-acetyl-4'-arylphenylalanines is described together with their incorporation in to a number of cationic peptoid antibacterial agents, one of which had an MIC of 7.8 μg/mL against Staphylococcus aureus. 
Introduction
With the increasing spread of antibacterial resistance, [1] [2] [3] including resistance by pathogenic bacteria to vancomycin, 4, 5 there is a compelling imperative for new antibacterials. 6, 7 In this context, we have undertaken a program investigating the design and synthesis of cyclic cationic peptoids linked by a hydrophobic scaffold as potential antibacterial agents, and thus far, have shown the binaphthyl 8 and carbazole scaffolds 9, 10 within these cyclic peptoids produce antibacterial agents, whilst the smaller indole based cyclic peptoids 11 failed to inhibit bacterial growth. Therefore, as part of this program targeting new peptoid derivatives as antibacterial agents and attempting to address the resistance mechanism against vancomycin, we investigated the synthesis of novel hydrophobic amino acids and their subsequent incorporation into acyclic cationic peptides. These peptides were designed to further explore the effect of hydrophobicity and the role of cationic residues within the peptide. The synthesis and methodology of the novel hydrophobic amino acids, their incorporation into cationic peptides and aspects of their in vitro antibacterial activity are reported in this paper. 
Chemistry
The strategy employed to prepare the two hydrophobic amino acids preceded via a common trimethylstannyl amido acid 5, which was prepared from phenylalanine in four steps (Scheme 1). This common intermediate was then coupled to either 9-bromoanthracene or 9-bromophenanthrene via a Stille coupling 13 protocol followed by subsequent saponification to yield the hydrophobic amido acids 7a and 7b (Scheme 1).
Therefore, iodination of phenylalanine was performed as previously described 14 to produce p-iodophenylalanine 2, which was isolated in quantitative yield. Esterification of 2 with MeOH/SOCl 2 afforded the methyl ester 3 as the hydrochloride salt in excellent yield, which was carried forward to the N-acetyl derivative 4 without further purification (Scheme 1). The key trimethylstannyl intermediate 5 was prepared following the procedure of Morera et al., 15 in 76% yield. This methodology was favoured over previously reported methods, 16 due to the faster reaction time in preparing the aryltrimethylstannane over the aryltributylstannane, significantly decreasing the possibility of racemization at the  position of the amido ester.
The hydrophobic amido esters 6a and 6b, were prepared via a Stille coupling methodology 14, 15 in 67% and 59% yields, respectively (Scheme 1). The ligand of choice for this reaction was tri-o-tolylphosphine, as phenyl transfer to the amino acid was observed when triphenylphosphine was present as the ligand. It was also found that increasing the temperature above 85 o C resulted in faster reaction times and also resulted in partial racemization of the -stereocentre of the amido ester. However, at 70 o C, no racemization was observed. Partial racemization of these products formed at the higher temperature was detected from 1 H NMR analysis of their products 12a,b (Scheme 2) that showed NMR signals for a minor diastereomer. The desired free acid form was obtained by saponification to afford 7a and 7b in 90% and 55% yield, respectively. The peptide fragment 10 was prepared employing a well established EDCI peptide coupling methodology and a Fmoc protection/deprotection protocol. [8] [9] [10] [11] This fragment was coupled to 7a and 7b to give the protected tripeptoids 11a and 11b, respectively (Scheme 2). N-Boc deprotection of 11a and 11b by exposure to TFA, followed by anion exchange with HCl provided the hydrochloride salts 12a and 12b, respectively (Scheme 2). 
In vitro antibacterial activity
The synthesized hydrophobic and cationic peptoids 12a, 12b, 20a, 20b and 20c were In contrast to the activity shown against S aureus, the cationic peptoids 12a, 12b, 20a, and 20b, were not active against Enterococcus faecalis strains (both vancomycin sensitive and resistant strains); MIC values >125 µg/mL were obtained against these strains and the same results were seen with the peptoid 20c.
Conclusions
We have developed a useful method for preparing the novel biaryl hydrophobic amido acids 7a,b via Stille coupling reactions. This method could potentially be employed to prepare other novel biaryl phenylalanine derivatives. We have shown that incorporation of these hydrophobic amido acid residues into cationic peptides resulted in peptoids having significant antibacterial activity against S. aureus when compared to a less hydrophobic, O-allyltyrosine analogue 20c. These results highlight the importance of hydrophobicity within the peptoid for antibacterial activity and provide a platform for further development of antimicrobial agents with improved activity against S. aureus.
Experimental

Chemistry
Chemical Ionisation (CI) mass spectra were obtained on a Shimadzu QP-5000 mass spectrometer by a direct insertion technique (electron beam density 70 eV). Electrospray ionization (ESI) mass spectra were obtained on a VG Quattro spectrometer. Highresolution mass spectra (HRMS) were determined on a VG Autospec spectrometer or on a micromass QTof2 spectrometer using polyethylene glycol as the internal standard. The m/z values are stated with their peak intensity percentages in parentheses. Optical rotations were measured using a Jasco DIP-370 digital polarimeter with a 10 mm path length. Proton and carbon nuclear magnetic resonance (NMR) spectra were determined in Compound numbering is based on that of compound 20 as shown in Scheme 3. All compounds were judged to be greater than 95% purity based upon 
General synthetic procedure for peptide coupling (Procedure B)
To a solution of the acid (1 equiv.) in DMF (10 mL per 1 mmol of substrate) at room temperature was added HOBt (1.1 equiv.), EDCI (1 equiv.) and the amine (1.2 equiv.). If the amine was a hydrochloride salt, DIPEA (1 equiv.) was also added. The mixture was allowed to stir for 16 h before dilution with EtOAc (30 mL) and washing with water (30 mL) and brine (30 mL). The organic fraction was dried (MgSO 4 ) and further purified by column chromatography if required.
General synthetic procedure for N-Fmoc Deprotection (Procedure C)
The Fmoc protected amine was stirred in 1% piperidine/acetonitrile (5 mL per 1 mmol of substrate) for 3 h at RT. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography (15:1, CH 2 Cl 2 /MeOH) to yield the free amine.
(S)-2-Amino-3-(4-iodophenyl)propanoic acid 2
To a solution (S)-2-amino-3-phenylpropanoic acid (4.01 g, 24.3 mmol) in acetic acid (22 mL) was added sulfuric acid (2.9 mL, 5.14 mmol), iodine (2.47 g, 4.7 mmol) and sodium iodate (1.02 g, 5.14 mmol). The mixture was heated to 70 o C and allowed to stir at this temperature for 16 h before an additional portion of sodium iodate (1.02 g, 5.14 mmol) was added. The reaction was left for a further 2 h before being concentrated, dissolved in MeOH (20 mL) and treated with NaOH (60 mL). The mixture was left to precipitate out of the basic solution overnight and the resulting solid was filtered by vacuum filtration to yield the title compound 2 (7.07 g, 24.3 mmol, 100%) as a pink solid, which had spectral data in agreement with that reported. 14 
Methyl (2S)-2-amino-3-(4-iodophenyl)propanoate hydrochloride 3
To a solution of 2 (2.00 g, 6.87 mmol) in MeOH (10 mL 
Methyl (2S)-2-acetamido-3-(4-iodophenyl)propanoate 4
To a solution of 3 (2.25 g, 6.80 mmol) in 10% HCl (10 mL) at 0 o C was added 4M sodium acetate (115 mL) and the resulting reaction was allowed to stir whilst equilibrating to 0 o C. Acetic anhydride (50 mL) was added and the reaction allowed to proceed with vigorous stirring. After 1 h the product was collected by vacuum filtration, dissolved in ethyl acetate (30 mL) and washed with 2M sodium bicarbonate (2 x 30 mL).
The organic layer was dried and evaporated to yield the title compound 4 ( 
Methyl (2S)-2-acetamido-3-(4-[9-anthracenyl]phenyl)-propanoate 6a
Methyl (2S)-2-acetamido-3-(4-[9-phenanthrenyl]phenyl)propanoate 6b
A 
(2S)-2-Acetamido-3-(4-[9-anthracenyl]phenyl)propanoic acid 7a
To a solution of 6a (80 mg, 0.20 mmol) in THF/water, 2:1 (3 mL) was added lithium hydroxide monohydrate (17 mg, 0.40 mmol) and the resulting suspension was allowed to stir for 16 h. The reaction mixture was diluted with water (30 mL) and the THF was removed by evaporation. 
(2S)-2-Acetamido-3-(4-[9-phenanthrenyl]phenyl)propanoic acid 7b
To a solution of 6b (124 mg, 0.31 mmol) in THF/water, 2:1 (9 mL) was added lithium hydroxide monohydrate (26 mg, 0.62 mmol) and the resulting suspension was allowed to stir for 16 h. The reaction mixture was diluted with water (30 mL) and the THF was removed by evaporation. 
Methyl (2S,5S)-2-allyl-3-aza-9-(tert-butoxycarboxamido)-5-(9H-9-fluorenylmethyloxycarboxamido)-4-oxononanoate 9
To a solution of 8 580.3023, found 580.3025.
Methyl (2S,5S)-2-allyl-5-amino-3-aza-9-(tert-butoxycarboxamido)-4-oxononanoate 10
The title compound was synthesized using the general N-Fmoc deprotection procedure 
Benzyl (2S)-2-amino-4-pentenoate hydrochloride 14
To a solution of 13 (225 mg, 1.96 mmol) in benzyl alcohol (5 mL) was added thionyl chloride (2 mL) and the resulting mixture was allowed to stir for 16 h before addition of diethyl ether (30 mL) and extraction with water (3 x 30 mL). The aqueous layer was concentrated, diluted with 2M sodium bicarbonate (20 mL), and extracted with CH 2 Cl 2 (3 x 30 mL). The combined organic fractions were dried and acidified with 1M HCl/diethyl ether (2 mL) and evaporated. 
Benzyl (2S,5R)-2-allyl-3-aza-5-(9H-9-fluorenylmethyloxycarboxamido)-4-oxo-8-[(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonyl)guanidino]octanoate 15
The title compound was synthesised using the general peptide coupling procedure 
Benzyl (2S,5R)-2-allyl-5-amino-3-aza-8-[(2,2,5,7,8-pentamethyl-3,4-dihydro-2H-
6-chromenylsulfonamido)guanidino]-4-oxooctanoate 16
Benzyl (2S,5R,8R)-2-allyl-3,6-diaza-12-(tert-butoxycarboxamido)-8-(9H-9-fluorenylmethyloxycarboxamido)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7dioxododecanoate 17
The title compound was synthesised using the general peptide coupling procedure 143.5, ArC8a"" and ArC9a""; 141.1, ArC4a"" and ArC4b""; 135.3, ArC7"'; 135.2, ArC5"'; 134.8, C2'; 128.4, ArC; 128.2, ArC; 128.1, ArC; 127.5, ArC; 126.9, ArCH2"" and ArCH7""; 125.2, ArCH3"" and ArCH6""; 125.0, ArCH4"" and ArCH5""; 124.0, ArC8"'; 119.8, ArC1"" and ArC8""; 118.9, C3'; 117.9, ArC4a"'; 79.0, C(CH 3 ) 3 ; 73. 
Benzyl (2S,5R,8R)-2-allyl-8-amino-3,6-diaza-12-(tert-butoxycarboxamido)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7dioxododecanoate 18
Methyl (2S,5S,8S)-2-allyl-8-(4-[9-anthrecenyl]benzyl)-3,6,9-triaza-5-(4-[tertbutoxycarboxamido]butyl)-4,7,10-trioxoundecanoate 11a
The title compound was synthesised using the general peptide coupling procedure The title compound was synthesised using the general peptide coupling procedure ArCH6"'; 129.9, ArCH3"' and ArCH5"'; 129.2, ArCH1""; 128.6, ArCH3""; 127.5, ArCH6""; 126.8, ArCH1""; 126.6, ArCH5""; 126.5, ArCH10""; 122.8, ArCH2""; 122. The title compound was synthesized using the general N-Boc deprotection procedure 132.9, ArCH2"' and ArCH6"'; 132.4, ArC4a"" and ArC10a""; 131.5, ArC8a"" and ArC9a""; 130.4, ArCH4"" and ArCH5""; 130.1, ArCH3"' and ArCH5"'; 129.5, ArCH10""; 127.7, ArCH8"" and ArCH1""; 126.5, ArCH2"" and ArCH7""; 126. -3,6,9-triaza-5-butylamino-4,7,10-trioxo-8-(4-[9-[phenanthrenyl] 
Methyl (2S,5S,8S)-2-allyl-5-(4-aminobutyl)
Benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-8-(4-aminobutyl)-3,6,9,12-tetraaza-5-(3-[guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate hydrochloride 20c
The title compound was synthesized using the general N-Boc deprotection procedure 
